Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
1 report, 1 independent
Updated Aug 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Alnylam Pharmaceuticals
biopharmaceutical company
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
-
Ionis Pharmaceuticals
American pharmaceutical company
Nothing else this week.
Related events
- Oracle Corporation and AstraZeneca announced a collaboration to accelerate clinical research.
- Replimune Group received FDA accelerated approval, and Mestag Therapeutics appointed new board members, including Victor Sandor and Philip Astley-Sparke.
- AstraZeneca and Teva Pharmaceutical Industries Limited are being compared as large-cap healthcare companies regarding their revenue and earnings.
- AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.
- Biofrontera and AstraZeneca are being compared as healthcare companies for investment.